Biotech website design: what investors and KOLs actually look for
What biotech and life science website design has to deliver for crossover investors, key opinion leaders, and senior talent. The structural decisions most companies get wrong.
A biotech CEO recently described a meeting with a crossover fund. The investor opened a laptop, pulled up the company’s website, and started clicking around for two minutes without saying anything. Then closed the laptop and asked the first real question.
That two-minute review is the meeting. Everything else is confirming or contradicting what the investor already concluded.
This is how life science website design actually works at the senior end of the market. The site isn’t a marketing brochure. It’s a triage tool used by sophisticated readers who are deciding in seconds whether you’re worth their next 30 minutes.
This article covers what biotech websites actually need to do, the structural decisions most companies get wrong, and the standards we apply when we build them.
The four jobs a biotech website has to do
A life science company website serves four distinct readers, and each one is doing a different job on the same pages.
Investors triage. They want to know stage, mechanism, lead asset, key milestones, management team credibility, and intellectual property posture. They want this in 90 seconds. If they have to dig for it, the site has failed them.
KOLs verify. They want to know the science. Mechanism of action, preclinical and clinical data, publication history, scientific advisory board, ongoing trials. They want the depth a poster session provides, not the marketing version.
Talent evaluates. They want to know team quality, lab or office environment if relevant, therapeutic area focus, hiring momentum, and what working there feels like. They’re cross-checking against three other offers.
Partners assess. Pharma BD, CRO partners, distribution partners. They want to know corporate maturity, partnership history, transaction posture, and the real point of contact for inbound.
A site optimized for one job will fail the other three. A site that tries to serve all four with one homogenized voice will fail all of them. The structural answer is to build distinct surfaces for distinct jobs, all under one coherent brand system.
The structure that works
Here’s the architecture we use for life science websites at clinical-stage and commercial-stage companies.
Home. The investor triage tool. Lead asset, mechanism, stage, next milestones, leadership team. Above the fold should answer “what is this company” without scrolling. Below the fold should answer “should I take a meeting” within 30 seconds.
Pipeline. A clear visual of every program, with stage, indication, and mechanism. This is the page investors and KOLs scan most. The pipeline visual should be the most carefully designed asset on the site.
Science. The KOL surface. Mechanism deep dives, key data, publication links, scientific rationale. This is where the company shows it understands its own science, not just markets around it.
Team. Leadership, scientific advisory board, board of directors. Real bios, not LinkedIn imports. The team page is one of the highest-traffic pages on every life science site we’ve built. Treat it accordingly.
News and Publications. Press releases, peer-reviewed publications, conference posters, media mentions. KOLs and investors check this page to assess momentum and rigor.
Careers. The talent surface. Open roles, but also a real description of what the company is and why somebody senior would join. Not “we’re a fast-paced, dynamic team.” Specifics about the science, the stage, and the people.
Investors. SEC filings if public, press releases, presentations, investor contacts. For private companies, this section is often a single page with the data room access process.
Patients or HCPs (if commercial). Patient-facing or HCP-facing materials, only if the company is at a stage where this is appropriate and compliant.
This is the floor. Most clinical-stage biotech sites have five of these and skip three. The five they have are usually fine. The three they skip are where they lose.
The pipeline visual is the most important asset on the site
If you have 15 minutes to invest in any single element of a biotech website, invest it in the pipeline visual.
Investors look at the pipeline first. They form an opinion about company stage, focus, and credibility from this one image. KOLs look at the pipeline to see what indications and mechanisms are active. Talent looks at the pipeline to assess whether there’s enough work to justify joining.
A pipeline visual should answer five questions instantly:
- How many programs?
- What stage is each one in?
- What indication is each one targeting?
- What’s the mechanism?
- What’s coming up next?
Most biotech pipeline visuals fail at one of these. The most common failure: stage is shown but milestones aren’t. The reader sees “Phase 2” but doesn’t know if that means “just dosed first patient” or “preparing readout in 60 days.” The difference is everything.
Build the pipeline as a system, not a static graphic. When the data updates, the pipeline updates. When a new milestone is hit, the page reflects it within hours, not at the next quarterly board meeting.
The data room mistake
Most clinical-stage biotechs hide their best material behind a data room request. The investor has to email, sign an NDA, get access, and only then sees the deck, the data, and the pipeline detail.
This made sense when websites were brochureware and data was sensitive. It makes less sense now. Investors triage 50 deals a quarter. They will not chase down a data room before they’ve decided you’re worth the chase.
The fix is calibrated transparency. Public surface that shows enough to earn the meeting. Stage, mechanism, key data points that are already in publications or press releases, leadership team. The data room then exists for what’s actually confidential: detailed financials, unpublished data, specific IP claims.
We’ve seen meaningful improvement in inbound investor interest from this single change. Sites that make the first impression do the work of getting to a meeting. Sites that make the investor work for the first impression don’t get the meeting.
The KOL surface is the underbuilt page
Almost every biotech we’ve audited has a thin science page. Two paragraphs of mechanism, a generic illustration, maybe a link to a publication. Then the rest of the site is investor-facing.
KOLs notice. They don’t say anything because they’re polite, but the impression is set. This company doesn’t take its own science seriously enough to explain it.
A real science page has:
- Mechanism of action explained at two depths. A short version for orientation. A longer version with figures, data, and links.
- Preclinical data with at least one chart that shows the actual signal.
- Clinical data summary, with appropriate fair balance and limitations.
- Publication list, organized by program.
- Scientific advisory board, with affiliations.
- Conference presence: posters, podium presentations, planned upcoming sessions.
The page should read like a serious scientific resource that a clinician would forward to a colleague. If it reads like marketing copy, KOLs will close the tab.
Why most biotech sites have voice problems
The voice problem in life science websites is consistent. The home page sounds like a CES press release (“transforming,” “pioneering,” “first-in-class”). The science page sounds like a scientific abstract (“we hypothesize that selective inhibition of”). The careers page sounds like LinkedIn marketing (“dynamic team,” “fast-paced environment”). The press releases sound like SEC filings.
Four voices, no coherence.
A real biotech voice has a consistent posture across surfaces, with deliberate variation by audience. The science page can be technical and the careers page can be warm. They can both still sound like the same company.
This is hard to do without a writer who has spent time in life science specifically. Generalist content people will copy whatever they see on other biotech sites, which is exactly the homogenized voice the company is trying to escape.
Performance and accessibility
A biotech website has to load fast and work for everyone, including KOLs reading on hospital wifi and investors checking on a phone in an airport.
The performance baseline:
- Largest contentful paint under 2.5 seconds on 3G.
- Total blocking time under 200 milliseconds.
- Cumulative layout shift under 0.1.
The accessibility baseline:
- WCAG 2.1 AA compliance, real not theoretical.
- Keyboard navigable for every interaction.
- Color contrast that works for color-blind readers.
- Proper heading hierarchy.
These aren’t nice-to-haves. They’re table stakes for a company that wants to be taken seriously by sophisticated readers in 2026.
The build versus rebuild decision
If you’re reading this and your site is older than two years, you probably need a rebuild, not a refresh. Two reasons.
Stack obsolescence. Sites built before 2023 are usually on platforms or frameworks that don’t support the performance and accessibility baselines above without significant rework. The cost of forcing a 2020 site to meet 2026 standards is often higher than rebuilding.
Content strategy obsolescence. The job a biotech site needs to do has changed. The reader expectations have changed. The competitive set looks different. A refresh leaves you with old structural decisions wearing new paint.
A real rebuild for a clinical-stage biotech runs 8 to 14 weeks, depending on complexity. The investment is meaningful and the return shows up in fundraising velocity, KOL engagement, and senior recruiting. We’ve seen all three change measurably within the first 90 days post-launch.
If you’re at a stage where the website is starting to drag on the science, we should talk. We’ve done this work for life science and advisory partners including Symbiosis Advisors, and we know the standards that matter.